Cargando…

223. Difference in Carbapenem Use by ASP Intervention in Japanese Healthcare Facilities

BACKGROUND: Antimicrobial stewardship program (ASP) interventions have been reported to reduce unnecessary antimicrobial use (AMU). In this study, we investigated the difference in the use of carbapenems by ASP intervention in Japanese healthcare facilities. METHODS: Data on two components of AMU an...

Descripción completa

Detalles Bibliográficos
Autores principales: Endo, Mio, Tsuzuki, Shinya, Asai, Yusuke, Tajima, Taichi, Matsunaga, Nobuaki, Hayakawa, Kayoko, Ohmagari, Norio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776956/
http://dx.doi.org/10.1093/ofid/ofaa439.267
_version_ 1783630798940798976
author Endo, Mio
Tsuzuki, Shinya
Asai, Yusuke
Tajima, Taichi
Matsunaga, Nobuaki
Hayakawa, Kayoko
Ohmagari, Norio
author_facet Endo, Mio
Tsuzuki, Shinya
Asai, Yusuke
Tajima, Taichi
Matsunaga, Nobuaki
Hayakawa, Kayoko
Ohmagari, Norio
author_sort Endo, Mio
collection PubMed
description BACKGROUND: Antimicrobial stewardship program (ASP) interventions have been reported to reduce unnecessary antimicrobial use (AMU). In this study, we investigated the difference in the use of carbapenems by ASP intervention in Japanese healthcare facilities. METHODS: Data on two components of AMU and ASP registered in Japan Surveillance for Infection Prevention and Healthcare Epidemiology (J-SIPHE) from January to December 2019, were used. Facilities with an infection control team in addition to an antimicrobial stewardship team responsible for the proper use of antimicrobial agents were included in the study. AMU data (such as DOT [Days of Therapy / 100 patient days]) are entered semi-automatically from medical fee statement (receipt) file at each facility. ASP intervention is divided into four categories 1) pre-authorization, 2) prospective audit and feedback (PAF), 3) PAF and required notification (RN), 4) RN. The Kruskal-Wallis test is performed to see overall difference and the Dunn test with the Bonferroni correction is done for each pair of categories. RESULTS: A total of 114 hospitals were included in the analysis. The median number of beds at participating facilities were 430 [IQR: 281–602], the median average hospital stay was 13.0 days [IQR: 11.4–15.2] and total number of inpatients per month was 10087 [6247–14536]. PAF and RN were the most common ASP interventions for carbapenems (62.5%), followed by RN (33.6%). The median DOT [IQR] of participating facilities were 2.1 [1.2–3.1] and 1) 0.7 [0.2–1.1], 2) 2.7 [2.1–3.4], 3) 2.1 [1.4–3.1] and 4) 2.0 [1.2–3.5] by ASP categories. There are significant differences between 1) and 2), 1) and 3), and 1) and 4) (p=0.014, p< 0.01 and p< 0.01, respectively) while the differences between 2) and 3), 2) and 4), and 3) and 4) are not significant (p=1.00). Table 1. Summary statistics of healthcare facilities by ASP Interventions [Image: see text] Figure 1. DOT by ASP Interventions [Image: see text] CONCLUSION: Only 3.5% of ASP interventions belong to 1) pre-authorization category and this might be due to the complexity of registration process. This category was found to have the lowest DOT among all ASP interventions in Japanese healthcare facilities. The variances of DOT were especially large in categories 3) and 4), and more detailed analyses would be necessary to evaluate their efficacies accurately. DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-7776956
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77769562021-01-07 223. Difference in Carbapenem Use by ASP Intervention in Japanese Healthcare Facilities Endo, Mio Tsuzuki, Shinya Asai, Yusuke Tajima, Taichi Matsunaga, Nobuaki Hayakawa, Kayoko Ohmagari, Norio Open Forum Infect Dis Poster Abstracts BACKGROUND: Antimicrobial stewardship program (ASP) interventions have been reported to reduce unnecessary antimicrobial use (AMU). In this study, we investigated the difference in the use of carbapenems by ASP intervention in Japanese healthcare facilities. METHODS: Data on two components of AMU and ASP registered in Japan Surveillance for Infection Prevention and Healthcare Epidemiology (J-SIPHE) from January to December 2019, were used. Facilities with an infection control team in addition to an antimicrobial stewardship team responsible for the proper use of antimicrobial agents were included in the study. AMU data (such as DOT [Days of Therapy / 100 patient days]) are entered semi-automatically from medical fee statement (receipt) file at each facility. ASP intervention is divided into four categories 1) pre-authorization, 2) prospective audit and feedback (PAF), 3) PAF and required notification (RN), 4) RN. The Kruskal-Wallis test is performed to see overall difference and the Dunn test with the Bonferroni correction is done for each pair of categories. RESULTS: A total of 114 hospitals were included in the analysis. The median number of beds at participating facilities were 430 [IQR: 281–602], the median average hospital stay was 13.0 days [IQR: 11.4–15.2] and total number of inpatients per month was 10087 [6247–14536]. PAF and RN were the most common ASP interventions for carbapenems (62.5%), followed by RN (33.6%). The median DOT [IQR] of participating facilities were 2.1 [1.2–3.1] and 1) 0.7 [0.2–1.1], 2) 2.7 [2.1–3.4], 3) 2.1 [1.4–3.1] and 4) 2.0 [1.2–3.5] by ASP categories. There are significant differences between 1) and 2), 1) and 3), and 1) and 4) (p=0.014, p< 0.01 and p< 0.01, respectively) while the differences between 2) and 3), 2) and 4), and 3) and 4) are not significant (p=1.00). Table 1. Summary statistics of healthcare facilities by ASP Interventions [Image: see text] Figure 1. DOT by ASP Interventions [Image: see text] CONCLUSION: Only 3.5% of ASP interventions belong to 1) pre-authorization category and this might be due to the complexity of registration process. This category was found to have the lowest DOT among all ASP interventions in Japanese healthcare facilities. The variances of DOT were especially large in categories 3) and 4), and more detailed analyses would be necessary to evaluate their efficacies accurately. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2020-12-31 /pmc/articles/PMC7776956/ http://dx.doi.org/10.1093/ofid/ofaa439.267 Text en © The Author 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Poster Abstracts
Endo, Mio
Tsuzuki, Shinya
Asai, Yusuke
Tajima, Taichi
Matsunaga, Nobuaki
Hayakawa, Kayoko
Ohmagari, Norio
223. Difference in Carbapenem Use by ASP Intervention in Japanese Healthcare Facilities
title 223. Difference in Carbapenem Use by ASP Intervention in Japanese Healthcare Facilities
title_full 223. Difference in Carbapenem Use by ASP Intervention in Japanese Healthcare Facilities
title_fullStr 223. Difference in Carbapenem Use by ASP Intervention in Japanese Healthcare Facilities
title_full_unstemmed 223. Difference in Carbapenem Use by ASP Intervention in Japanese Healthcare Facilities
title_short 223. Difference in Carbapenem Use by ASP Intervention in Japanese Healthcare Facilities
title_sort 223. difference in carbapenem use by asp intervention in japanese healthcare facilities
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776956/
http://dx.doi.org/10.1093/ofid/ofaa439.267
work_keys_str_mv AT endomio 223differenceincarbapenemusebyaspinterventioninjapanesehealthcarefacilities
AT tsuzukishinya 223differenceincarbapenemusebyaspinterventioninjapanesehealthcarefacilities
AT asaiyusuke 223differenceincarbapenemusebyaspinterventioninjapanesehealthcarefacilities
AT tajimataichi 223differenceincarbapenemusebyaspinterventioninjapanesehealthcarefacilities
AT matsunaganobuaki 223differenceincarbapenemusebyaspinterventioninjapanesehealthcarefacilities
AT hayakawakayoko 223differenceincarbapenemusebyaspinterventioninjapanesehealthcarefacilities
AT ohmagarinorio 223differenceincarbapenemusebyaspinterventioninjapanesehealthcarefacilities